AEGEAN: a phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC

被引：0

作者：

Schumann, C. ^{[1
]}

Heymach, J. V. ^{[2
]}

Harpole, D. ^{[3
]}

Mitsudomi, T. ^{[4
]}

Taube, J. M. ^{[5
]}

Galffy, G. ^{[6
]}

Hochmair, M. ^{[7
]}

Winder, T. ^{[8
]}

Zukov, R. ^{[9
]}

Garbaos, G. ^{[10
]}

Gao, S. ^{[11
]}

Kuroda, H. ^{[12
]}

You, J. ^{[13
]}

Lee, K. -Y. ^{[14
]}

Antonuzzo, L. ^{[15
]}

Aperghis, M. ^{[16
]}

Doherty, G. J. ^{[16
]}

Mann, H. ^{[16
]}

Fouad, T. M. ^{[17
]}

Reck, M. ^{[18
]}

Weissinger, F. ^{[19
]}

机构：

[1] Clin Allgau Kempten & Immenstadt, Thorac Surg, Kempten, Germany

[2] MD Anderson Canc Ctr, Houston, TX USA

[3] Duke Univ, Med Ctr, Durham, NC USA

[4] Kindai Univ, Fac Med, Osaka, Japan

[5] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA

[6] Pest Cty Pulmonol Hosp, Torokbalint, Hungary

[7] Klin Floridsdorf, Vienna, Austria

[8] Landeskrankenhaus Feldkirch, Feldkirch, Austria

[9] Krasnoyarsk State Med Univ, Krasnoyarsk, Russia

[10] Fdn Estudios Clin, Santa Fe, NM USA

[11] Natl Clin Res Ctr Canc, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China

[12] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[13] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[14] Shuang Ho Hosp, New Taipei, Taiwan

[15] Careggi Univ Hosp, Florence, Italy

[16] AstraZeneca, Cambridge, England

[17] AstraZeneca, New York, NY USA

[18] Lung Clin Grosshansdorf, Grosshansdorf, Germany

[19] Evangel Klinikum Bethel, Bielefeld, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V47

引用

页码：8 / 9

页数：2

共 50 条

[21] A phase Ib trial of neoadjuvant/adjuvant durvalumab plus /- tremelimumab in locally advanced renal cell carcinoma (RCC).
Ornstein, Moshe Chaim
Zabell, Joseph
Wood, Laura S.
Hobbs, Brian
Devonshire, Sarah
Martin, Allison
Allman, Kimberly D.
Rao, Arpit
Gilligan, Timothy D.
Campbell, Steven
Krishnamurthi, Venkatesh
Rini, Brian, I
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[22] Neocoast-2: Efficacy and Safety of Neoadjuvant Durvalumab (D) plus Novel Anticancer Agents plus CT and Adjuvant D ± Novel Agents in Resectable NSCLC
Cascone, T.
Florian, G.
Bonanno, L.
Lieberman, M.
Bylicki, O.
Insa, A.
Livi, L.
Corre, R.
Egenod, T.
Bieslka, A.
Yohannes, A.
Mager, R.
He, Y.
Dowson, A.
McGrath, L.
Kumar, R.
Grenga, I.
Spicer, J.
Forde, P.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S1 - S2
[23] Neoadjuvant Sintilimab plus Chemotherapy in EGFRmutant NSCLC Followed by adjuvant Osimertinib or Observation: A Phase II CTONG2104 Trial
Zhang, C.
Jiang, B-y
Yan, L-x
Chen, Z-y
Lv, C.
Li, Y-s
Dong, S.
Liao, R-q
Yang, X-n
Zhou, Q.
Wu, Y-L
Zhong, W-z
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S119 - S120
[24] Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.
Cascone, Tina
Provencio, Mariano
Sepesi, Boris
Lu, Shun
Aanur, Nivedita
Li, Sunney
Spicer, Jonathan
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[25] POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC
Mok, T.
Johnson, M.
Garon, E.
Peters, S.
Soria, J.
Wang, L.
Jarkowski, A.
Dennis, P.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1974 - S1974
[26] POSEIDON: A phase 3 study of first-line Durvalumab ± Tremelimumab plus chemotherapy vs chemotherapy alone in metastatic NSCLC
Thomas, M.
Grohe, C.
Eberhardt, W.
Rawluk, J.
Reck, M.
Laack, E.
Wesseler, C.
Rittmeyer, A.
Alt, J.
Reinmuth, N.
Griesinger, F.
Kern, J.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 295 - 295
[27] MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
Janjigian, Yelena Y.
Van Cutsem, Eric
Muro, Kei
Wainberg, Zev
Al-Batran, Salah-Eddin
Hyung, Woo Jin
Molena, Daniela
Marcovitz, Michelle
Ruscica, Dario
Robbins, Scott H.
Negro, Alejandra
Tabernero, Josep
FUTURE ONCOLOGY, 2022, 18 (20) : 2465 - 2473
[28] NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
de Castro Jr, Gilberto
Rizvi, Naiyer A.
Schmid, Peter
Syrigos, Konstantinos
Martin, Claudio
Yamamoto, Nobuyuki
Cheng, Ying
Moiseyenko, Vladimir
Summers, Yvonne
Vynnychenko, Ihor
Lee, Sung Yong
Bryl, Maciej
Zer, Alona
Erman, Mustafa
Timcheva, Constanta
Raja, Rajiv
Naicker, Kirsha
Scheuring, Urban
Walker, Jill
Mann, Helen
Chand, Vikram
Mok, Tony
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01) : 106 - 119
[29] A randomized phase II study of cisplatin plus radiotherapy versus durvalumab plus radiotherapy followed by adjuvant durvalumab versus durvalumab plus radiotherapy followed by adjuvant tremelimumab and durvalumab in intermediate risk, HPV-positive, locoregionally advanced oropharyngeal squamous cell cancer (LA-OSCC) (Canadian Cancer Trials Group HN.9)
Spreafico, A.
Sultanem, K.
Chen, B.
Bratman, S. V.
Ringash, J.
Louie, A. V.
McNiven, A.
Whelan, K.
Hilton, J.
Yoo, J.
Machiels, J-P.
Licitra, L. F.
Oosting, S.
Waldron, J. N.
Siu, L. L.
Parulekar, W. R.
ANNALS OF ONCOLOGY, 2018, 29 : 399 - 399
[30] Neoadjuvant tislelizumab or placebo plus platinum-based chemotherapy followed by adjuvant tislelizumab or placebo in patients with resectable non-small cell lung cancer (NSCLC): A phase III trial in progress
Wang, C.
Wang, R.
Ma, Y.
Liang, X.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S746 - S746

← 1 2 3 4 5 →